Interferons are proteins that are crucial to the body's immune response. They help regulate the immune system and have effects that can modify certain diseases. For over 35 years, interferons have been used to treat a group of blood cancers known as myeloproliferative neoplasms (MPNs), which include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).
The interferons currently available are:
Interferons work by binding to specific receptors on the surface of cells. This binding triggers a series of actions inside the cell that help control and reduce the abnormal growth of blood cells. In particular, they can help reduce the number of mutated cells.
Their specific mechanism of action is focused on three main functions:
Interferons can be administered intramuscularly (injected into the muscle), subcutaneously (injected into the layer between fat and skin), or intravenously (injected into the vein by a trained health professional).
The initial use of interferons was challenging due to side effects. These issues have been improved by attaching a substance called polyethylene glycol (PEG) to the interferons, which increases interferon stability, prolongs their activity in the body, and reduces immune reactions.
There are, however, common side effects patients may experience while taking interferon therapy, such as:
Managing interferon-based therapies requires careful monitoring and sometimes switching from other treatments like hydroxyurea. Early interferon treatment can lower the risk of complications and slow disease progression.
With ongoing research focused on improving interferons' effectiveness and reducing their side effects, these therapies offer hope for better disease control and potentially longer periods of remission for patients with myeloproliferative neoplasms.
In conclusion, interferons are a significant treatment for myeloproliferative neoplasms, offering patients a more stable and tolerable option. With continued research and refinement, they hold the potential for even better outcomes in the future.
By securely creating a free account in HealthTree Cure Hub, you can stay updated on treatment advances, news, and education on your disease. Sign up for a free patient account today to get started. You can, too, contribute to finding a cure and help us do research!
Source:
Interferons are proteins that are crucial to the body's immune response. They help regulate the immune system and have effects that can modify certain diseases. For over 35 years, interferons have been used to treat a group of blood cancers known as myeloproliferative neoplasms (MPNs), which include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).
The interferons currently available are:
Interferons work by binding to specific receptors on the surface of cells. This binding triggers a series of actions inside the cell that help control and reduce the abnormal growth of blood cells. In particular, they can help reduce the number of mutated cells.
Their specific mechanism of action is focused on three main functions:
Interferons can be administered intramuscularly (injected into the muscle), subcutaneously (injected into the layer between fat and skin), or intravenously (injected into the vein by a trained health professional).
The initial use of interferons was challenging due to side effects. These issues have been improved by attaching a substance called polyethylene glycol (PEG) to the interferons, which increases interferon stability, prolongs their activity in the body, and reduces immune reactions.
There are, however, common side effects patients may experience while taking interferon therapy, such as:
Managing interferon-based therapies requires careful monitoring and sometimes switching from other treatments like hydroxyurea. Early interferon treatment can lower the risk of complications and slow disease progression.
With ongoing research focused on improving interferons' effectiveness and reducing their side effects, these therapies offer hope for better disease control and potentially longer periods of remission for patients with myeloproliferative neoplasms.
In conclusion, interferons are a significant treatment for myeloproliferative neoplasms, offering patients a more stable and tolerable option. With continued research and refinement, they hold the potential for even better outcomes in the future.
By securely creating a free account in HealthTree Cure Hub, you can stay updated on treatment advances, news, and education on your disease. Sign up for a free patient account today to get started. You can, too, contribute to finding a cure and help us do research!
Source:
about the author
Jimena Vicencio
Jimena is an International Medical Graduate and a member of the HealthTree Writing team. She has a passion for languages and is currently learning Japanese. In her free time, she loves playing with her cats. Jimena is also pursuing a bachelor's degree in journalism.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.